BiotechTube

Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

PLASMODIUM FALCIPARUM MALARIA

Conditions

PLASMODIUM FALCIPARUM MALARIA

Trial Timeline

Sep 1, 2003 → Jan 1, 2005

NCT ID
NCT00074841

About Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine

Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine is a phase 2/3 stage product being developed by Pfizer for PLASMODIUM FALCIPARUM MALARIA. The current trial status is completed. This product is registered under clinical trial identifier NCT00074841. Target conditions include PLASMODIUM FALCIPARUM MALARIA.

What happened to similar drugs?

0 of 2 similar drugs in PLASMODIUM FALCIPARUM MALARIA were approved

Approved (0) Terminated (0) Active (2)
🔄KLU156 + CoartemNovartisPhase 3
🔄Artemether-lumefantrineNovartisPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00084240Phase 2/3Terminated
NCT00074841Phase 2/3Completed

Competing Products

13 competing products in PLASMODIUM FALCIPARUM MALARIA

See all competitors
ProductCompanyStageHype Score
KLU156 + CoartemNovartisPhase 3
40
artemether:lumefantrine (2.5 mg:30 mg)NovartisPhase 2/3
30
INE963NovartisPhase 2
35
KAE609 + Piperaquine PhosphateNovartisPhase 1
21
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
35
KAF156 + Coartem + Lumefantrine Solid Dispersion FormulationNovartisPhase 2
35
Artemether-lumefantrineNovartisPhase 3
40
INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156NovartisPhase 2
42
KAF156 + LUM-SDF + CoartemNovartisPhase 2
35
Ferroquine (SSR97193) + Placebo + artesunateSanofiPhase 2
27
Ferroquine SSR97193 + ArtefenomelSanofiPhase 2
27
Artefenomel (OZ439) + Ferroquine (SSR97193)SanofiPhase 2
35
Meplazumab for Injection + Sterile normal saline (0.9%)Pacific BiosciencesPhase 1
11